Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss

v3.23.1
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2022
Dec. 31, 2021
Condensed Consolidated Statements of Operations and Comprehensive Loss        
Revenues $ 0 $ 0   $ 84
Operating expenses:        
Research and development 2,779 1,859 $ 5,327 2,993
General and administrative 7,794 5,372 12,882 9,547
Total operating expenses 10,573 7,231 18,209 12,540
Operating loss (10,573) (7,231) (18,209) (12,456)
Other income (expense):        
Interest expense (31) 0 (31)  
Interest income 41 35 140 71
Royalty income 0 5   5
Total other income (expense) 10 40 109 76
Consolidated net loss from continuing operations (10,563) (7,191) (18,100) (12,380)
Net loss attributable to noncontrolling interest 0 0   1
Net loss attributable to iBio, Inc. from continuing operations (10,563) (7,191) (18,100) (12,379)
Preferred stock dividends - iBio CDMO Tracking Stock 0 (22) 0 (88)
Net loss available to iBio, Inc. stockholders from continuing operations (10,563) (7,213) (18,100) (12,467)
Loss from discontinued operations (22,990) (4,729) (33,583) (8,480)
Net loss available to iBio, Inc. stockholders (33,553) (11,942) (51,683) (20,947)
Comprehensive loss:        
Consolidated net loss (33,553) (11,920) (51,683) (20,860)
Other comprehensive loss - unrealized gain ( loss) on debt securities 56 (27) 46 (28)
Comprehensive loss $ (33,497) $ (11,947) $ (51,637) $ (20,888)
Loss per common share attributable to iBio, Inc. stockholders - basic - continuing operations $ (1.08) $ (0.83) $ (1.94) $ (1.43)
Loss per common share attributable to iBio, Inc. stockholders - diluted - continuing operations (1.08) (0.83) (1.94) (1.43)
Loss per common share attributable to iBio, Inc. stockholders - basic - discontinued operations (2.34) (0.54) (3.60) (0.97)
Loss per common share attributable to iBio, Inc. stockholders - diluted - discontinued operations (2.34) (0.54) (3.60) (0.97)
Loss per common share attributable to iBio, Inc. stockholders - basic - total (3.42) (1.37) (5.54) (2.40)
Loss per common share attributable to iBio, Inc. stockholders - diluted - total $ (3.42) $ (1.37) $ (5.54) $ (2.40)
Weighted-average common shares outstanding - basic 9,807 8,715 9,324 8,715
Weighted-average common shares outstanding - diluted 9,807 8,715 9,324 8,715